Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Delayed cardiac toxicity from anthracycline therapy.

L Steinherz1, P Steinherz

  • 1Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, N.Y.

Pediatrician
|January 1, 1991
PubMed
Summary

Childhood cancer survivors treated with anthracyclines face long-term risks of abnormal heart function, potentially leading to serious cardiac events years later. Regular cardiac monitoring is essential for early detection and management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.

Leukemia·2009
Same author

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1999
Same author

Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients.

Blood·1999
Same author

Antileukemia activity of a natural killer cell line against human leukemias.

Clinical cancer research : an official journal of the American Association for Cancer Research·1998
Same author

A Phase II clinical trial of idarubicin administered to children with relapsed brain tumors.

Cancer·1998

Area of Science:

  • Cardiology
  • Oncology
  • Pediatric Medicine

Background:

  • Anthracycline chemotherapy is a cornerstone in treating various childhood cancers.
  • Long-term survivors of pediatric malignancies are at increased risk for late-onset cardiac toxicity.
  • Cardiac decompensation and heart failure can manifest years after anthracycline completion.

Purpose of the Study:

  • To highlight the significant risk of cardiac dysfunction in childhood cancer survivors treated with anthracyclines.
  • To emphasize the delayed onset of cardiac complications following anthracycline therapy.
  • To underscore the necessity of ongoing cardiac surveillance for this high-risk population.

Main Methods:

  • Review of existing literature on anthracycline cardiotoxicity in pediatric cancer survivors.
  • Analysis of long-term follow-up data regarding cardiac function and outcomes.
  • Identification of key indicators for cardiac decompensation and arrhythmias.

Main Results:

  • A high incidence of abnormal cardiac function is observed in survivors.
  • Cardiac events, including decompensation and mortality, can occur many years post-treatment.
  • The risk is directly associated with anthracycline exposure during childhood cancer treatment.

Conclusions:

  • Childhood cancer survivors treated with anthracyclines require lifelong monitoring for cardiac health.
  • Periodic evaluation of cardiac function and rhythm is crucial for early intervention.
  • Proactive cardiac care can mitigate the long-term adverse effects of anthracycline therapy.

Related Experiment Videos